Status:
COMPLETED
Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia
Lead Sponsor:
Marcus Saemann
Conditions:
Hyperglycemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Treat-to-target trial of basal Insulin in Post-transplant hyperglycemia (TIP): efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosuppression DE...
Detailed Description
DESIGN / PHASE: Prospective, single-center, randomized, parallel group, controlled, phase II study. STUDY PLANNED DURATION: First patient First visit 1Q 2009 Last patient First visit 4Q 2009 Last p...
Eligibility Criteria
Inclusion
- renal transplantation (deceased or living donor)
- eligibility for the standard immunosuppression of our center, consisting of tacrolimus, mycophenolate mofetil or mycophenolic acid, dexamethasone/prednisone triple therapy
- informed consent of the patient
Exclusion
- patients with type 1 or type 2 diabetes
- allergy against long-acting insulin
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00830297
Start Date
January 1 2009
End Date
May 1 2011
Last Update
September 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna, Department of Internal Medicine III
Vienna, Austria, 1090